Multiple hereditary exostoses (MHE) is also known a hereditary multiple exostoses, osteochondromatosis, or diaphyseal aclasis, depending primarily upon the geographic location. It was renamed to multiple osteochondroma by the World Health Organisation in 2002; however, the renaming remains controversial, and many researchers as well as patients and their families prefer to use the original designation. This issue was discussed at the Third International MHE Research Conference, but a consensus was unfortunately not reached.
Shop talk: Sugars, bones, and a disease called multiple hereditary exostoses†
Article first published online: 9 APR 2010
Copyright © 2010 Wiley-Liss, Inc.
Volume 239, Issue 6, pages 1901–1904, June 2010
How to Cite
Roehl, H. H. and Pacifici, M. (2010), Shop talk: Sugars, bones, and a disease called multiple hereditary exostoses. Dev. Dyn., 239: 1901–1904. doi: 10.1002/dvdy.22290
- Issue published online: 17 MAY 2010
- Article first published online: 9 APR 2010
- Manuscript Accepted: 4 MAR 2010
- Wellcome Trust. Grant Number: 072346/Z/03/Z
- heparan sulfate
On October 29, 2009, researchers and physicians gathered at the Sheraton Four Points Hotel in Boston for 4 days to discuss a disease called multiple hereditary exostoses (MHE). MHE is an autosomal dominant disease that is associated with mutations in two enzymes that are required for heparan sulfate (HS) synthesis. Children with the disease form numerous benign bone tumors (osteochondromas) and have >2% chance of developing chondrosarcoma. The aim of the meeting was to generate new ideas for the diagnoses, treatment, and cure of this disease. Discussions ranged from orthopedic surgical treatment and patients' personal experiences to fundamental questions in skeletal biology and the precise molecular role that HS plays in developmental signaling pathways. Developmental Dynamics 239:1901–1904, 2010. © 2010 Wiley-Liss, Inc.